Key Takeaways
Becton, Dickinson and Co. (NYSE: BDX) on Tuesday launched a new central line system designed to cut insertion time by 50 percent, a major development in a procedure performed millions of times annually in the U.S. The BD® CentroVena One™ Insertion System is the first all-in-one device for central venous catheter (CVC) placement, aiming to improve patient safety and clinical workflow.
"CentroVena One™ represents the most meaningful advancement in central line insertion since the technique was first introduced nearly seven decades ago," Ron Silverman, executive vice president and chief medical officer at BD, said. "By reducing procedural steps, helping protect against preventable complications and simplifying one of the most stressful procedures clinicians perform, we're supporting safer, faster care for patients when every second counts."
The new system, which received U.S. Food and Drug Administration 510(k) clearance, consolidates the introducer needle, syringe, guidewire, and catheter into a single unit. This integrated design reduces procedural steps by 30% compared to the traditional method, which involves multiple component exchanges. The time-reduction claim is based on a head-to-head simulation study involving 49 participants.
This launch marks BD's entry into the acute CVC market, positioning it against other major medical device firms like Baxter (BAX) and Alcon (ALC). For investors, the innovation could be a significant growth driver for BD, whose stock has been trading near its 52-week low. The device addresses common and costly complications of traditional CVC placement, including bloodstream infections, arterial injury, and pneumothorax, which can affect hospital spending and reimbursement trends.
Traditional central line placement is a complex process that carries risks of contamination and workflow delays. The CentroVena One™ system is designed to mitigate these issues by minimizing touchpoints and streamlining the process. Key features include a pre-loaded, kink-resistant guidewire and a catheter with a self-dilating tip, which eliminates a separate dilation step.
UNC Health Blue Ridge was one of the first health systems to use the device in a clinical evaluation. "What stands out in our early experience with CentroVena One™ is its intentional design around real-world clinical challenges – streamlining catheter placement while reducing opportunities for error, sterile field breaches and overall workload," said Anthony Frank, chief medical officer at UNC Health Blue Ridge.
The system also incorporates safety elements like an integrated drape clip to prevent guidewire embolism and passive needle safety to reduce needlestick injuries. Its acceptance into the FDA's Safer Technologies Program (STeP) highlights its potential to significantly improve the safety of a common medical procedure.
This article is for informational purposes only and does not constitute investment advice.
